Phase II trial with navelbine + cisplatin + etoposide in the treatment of inoperable non-small cell lung carcinoma

Richardet, Eduardo Arnoldo, Carranza, L., Uribe, A., Tolocka, H., Cresta, Cecilia, Uribe, E. and Uribe, M. (1995) Phase II trial with navelbine + cisplatin + etoposide in the treatment of inoperable non-small cell lung carcinoma. Revista de la Facultad de Ciencias Médicas (Córdoba, Argentina), 53 (1). pp. 27-32. ISSN 0014-6722

PDF - Versión aceptada Disponible bajo Licencia CC Atribución-NoComercial-SinDerivadas 4.0 Internacional. Descargar (188kB)

Resumen

40 patients with advanced non-small cell lung cancer not previously treated were included in a study at phase II with vinorelbine 20 mg/Sq.m days 1 and 8, etoposide 60 mg/sq.m days 1-3 and cisplatin 75 mg/sq.m day 1 each 28 days for 6 cycles. There were 31 men and 9 women, being the average age of 54 years, with "performance Status" grade 0-2. All of them could be evaluated for toxicity and 31 for responsiveness. 10 patients were in stage IIIb and 21 at stage IV. 42% of objective responses were obtained and an overall survival of 9 months, which justifies further studies.

Tipo de documento:	Artículo
Palabras clave:	Adult. Aged. Antineoplastic Agents, Phytogenic. Antineoplastic Combined Chemotherapy Protocols. Carcinoma, Non-Small-Cell Lung. Cisplatin. Etoposide. Female. Humans. Lung Neoplasms. Male. Middle Aged. Vinblastine.
Temas:	R Medicina > R Medicina (General)
Unidad académica:	Universidad Católica de Córdoba > Facultad de Ciencias de la Salud
Google Académico:	Ver citaciones
URI:	http://pa.bibdigital.ucc.edu.ar/id/eprint/3717

Editar ítem